Key terms
About ONCT
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ONCT news
Apr 17
7:45am ET
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
Apr 15
6:50am ET
Oncternal Therapeutics price target lowered to $28 from $30 at H.C. Wainwright
Apr 15
6:17am ET
Buy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming Catalysts
Mar 08
4:43pm ET
Oncternal Therapeutics files $250M mixed securities shelf
Mar 08
8:50am ET
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Mar 07
4:06pm ET
Oncternal Therapeutics reports Q4 EPS ($3.11), consensus (3.07)
Feb 13
7:37am ET
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Feb 01
9:02am ET
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
No recent press releases are available for ONCT
ONCT Financials
Key terms
Ad Feedback
ONCT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ONCT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
